Filspari (sparsentan) for the Reduction of Proteinuria in IgA Nephropathy, US
Filspari (sparsentan) is indicated for reducing urine protein levels (proteinuria) in adults with primary immunoglobulin A nephropathy (IgAN), who are …
Projects
-
-
ICOTYDE (icotrokinra) for the Treatment of Plaque Psoriasis, US
ICOTYDE™ (icotrokinra) is the first and only targeted oral peptide indicated for the treatment of moderate-to-severe plaque psoriasis (PsO) in …
-
IMDELLTRA (tarlatamab) for the Treatment of Extensive-Stage Small Cell Lung Cancer, US
IMDELLTRA™ (tarlatamab) is a first-in-class immunotherapy indicated for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in adult patients …
-
Tzield (teplizumab-mzwv) for the Treatment of Type 1 Diabetes, US
Tzield™ (teplizumab-mzwv) is the first and only therapy indicated to delay the progression to Stage 3 Type 1 diabetes (T1D) in …
-
Sunlenca (Lenacapavir) for the Treatment of HIV-1 Infection, US
Sunlenca® (lenacapavir) is a first-in-class capsid inhibitor indicated for the treatment of adults with multi-drug resistant human immunodeficiency virus-1 (HIV-1) …
-
Koselugo (selumetinib) for the Treatment of Neurofibromatosis Type 1, US
Koselugo® (selumetinib) is an oral mitogen-activated protein kinase (MEK) inhibitor indicated for the treatment of neurofibromatosis type 1 (NF1), a …
-
Kisunla (donanemab-azbt) for the Treatment of Early Alzheimer’s Disease, US
Kisunla™ (donanemab-azbt) is a disease-modifying therapy (DMT) for adults with early symptomatic Alzheimer’s disease (AD), encompassing those with mild cognitive …
-
Modeyso (dordaviprone) for the Treatment of Diffuse Midline Glioma, US
Modeyso™ (dordaviprone) is indicated for the treatment of adult and paediatric patients aged one year and older with diffuse midline …
-
Nucala (mepolizumab) for the Treatment of Hypereosinophilic Syndrome (HES), UK
Nucala® (mepolizumab) is the first biologic therapy indicated for the treatment of hypereosinophilic syndrome (HES) in adult and paediatric patients …
-
Jascayd (nerandomilast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF), US
Jascayd® (nerandomilast/BI 1015550) is a phosphodiesterase 4 (PDE4) inhibitor developed by Boehringer Ingelheim for the treatment of adults with idiopathic …
-
Briumvi (ublituximab-xiiy) for the Treatment of Multiple Sclerosis, US
Briumvi™ (ublituximab-xiiy) is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, …
-
EKTERLY (sebetralstat) for the Treatment of Hereditary Angioedema, USA
EKTERLY® (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute hereditary angioedema (HAE) attacks in adults and in children aged 12 …
-
IBTROZI for the Treatment of Non-small Cell Lung Cancer, US
IBTROZI™ (taletrectinib) is a tyrosine kinase inhibitor indicated for the treatment of adults with locally advanced or metastatic non-small cell …
-
Breyanzi for the Treatment of Large B-cell Lymphoma, US
Breyanzi (lisocabtagene maraleucel) is a CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy indicated for the treatment of adult patients with …
-
FORZINITY (elamipretide) for Muscle Strength in Barth syndrome, USA
FORZINITY™ (elamipretide HCl) is indicated to enhance muscle strength in adult and paediatric patients with Barth syndrome who weigh at …
